



(51) International Patent Classification:

C07K 16/08 (2006.01) A61K 39/395 (2006.01)
C07K 16/10 (2006.01) A61P 31/12 (2006.01)
A61K 38/16 (2006.01) A61P 31/14 (2006.01)
A61K 39/42 (2006.01)

(21) International Application Number:

PCT/US2018/020264

(22) International Filing Date:

28 February 2018 (28.02.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/465,379 01 March 2017 (01.03.2017) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Mil-
stein Building, Granta Park, Cambridge CB21 6GH (GB).

(72) Inventors; and

(71) Applicants: **LOBO, Brian** [US/US]; MedImmune, LLC,
One MedImmune Way, Gaithersburg, MD 20878 (US).
GOLDBERG, Deborah [US/US]; 6219 Sutton Court,
Elkridge, MD 21075 (US).


(74) Agent: **JOHNSON, Nancy, A.**; Mueeting, Raasch &
Gebhardt, P.A., P.O. Box 581336, Minneapolis, MN
55458-1336 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-RSV MONOCLONAL ANTIBODY FORMULATION

MEDI8897 REPRESENTATIVE DRUG PRODUCT STABILITY

Fig. 3

(57) Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

PCT

(PCT Rule 92*bis*.1 and
Administrative Instructions, Section 422)

JOHNSON, Nancy, A.
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581336
Minneapolis, MN 55458-1336
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (<i>day/month/year</i>) 26 September 2018 (26.09.2018)	
Applicant's or agent's file reference 490.00050201	IMPORTANT NOTIFICATION
International application No. PCT/US2018/020264	International filing date (<i>day/month/year</i>) 28 February 2018 (28.02.2018)

1. The following indications appeared on record concerning:		
☒ the applicant	☒ the inventor	☐ the agent ☐ the common representative
Name and Address LOBO, Brian GOLDBERG, Deborah	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: ☐ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence		
Name and Address	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	

3. Further observations, if necessary: The two persons identified in Box 1 have been now recorded as inventors only.

4. A copy of this notification has been sent to:		☐	the International Preliminary Examining Authority
☒	the receiving Office	☒	the designated Offices concerned
☐	the International Searching Authority	☐	the elected Offices concerned
☐	the Authority(ies) specified for supplementary search	☐	other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. +41 22 338 71 30	Authorized officer Suarez Javier e-mail pct.team9@wipo.int Telephone No. +41 22 338 74 09
--	---